Several key issues including standardisation and validation of ctDNA response criteria for predicting clinical outcomes in oncology still need to be addressed
Baseline and on-treatment changes in ctDNA may provide an early indication of response to experimental therapies
Results from the TRACERx study suggest a potential role of CHIP as a prognostic biomarker, but further research is needed
In the MATCH-R study, comprehensive profiling included successful sequencing of DNA and also of RNA, enabling the detection of actionable genomic alterations
The study involved patients with HR-positive/HER2-negative localised disease, but additional analyses are required to describe implications for clinical practice.
At Molecular Analysis for Precision Oncology (MAP) Congress 2023, international experts discuss the future of histology-agnostic drug development and clinical trial design
Identifying the trigger that switches neutrophils from protumour to antitumour activity in the tumour microenvironment could open the door to new therapeutic options
Recent findings regarding the role of tumour promoters in cancer development should lead to a review of the mechanisms of action of existing environmental carcinogens
Continued collaboration to identify new molecular targets and treatments can build on existing success
Safety and biomarker status data of the PARP7 inhibitor RBN-2397 and the IgG4 monoclonal antibody SRK-181 presented at the ESMO TAT Congress 2023
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.